{"id":182433,"date":"2015-09-22T19:47:00","date_gmt":"2015-09-23T00:47:00","guid":{"rendered":"https:\/\/www.panix.com\/~msaroff\/40years\/2015\/09\/22\/this-is-a-clear-case-of-immoral-parasitism-and-its-pharma-so-not-the-surprise\/"},"modified":"2015-09-22T19:47:00","modified_gmt":"2015-09-23T00:47:00","slug":"this-is-a-clear-case-of-immoral-parasitism-and-its-pharma-so-not-the-surprise","status":"publish","type":"post","link":"https:\/\/www.panix.com\/~msaroff\/40years\/2015\/09\/22\/this-is-a-clear-case-of-immoral-parasitism-and-its-pharma-so-not-the-surprise\/","title":{"rendered":"This Is a Clear Case of Immoral Parasitism, and It’s Pharma, so Not the Surprise"},"content":{"rendered":"

<\/a>You know the story, hedge fund puke buys a pharmaceutical firm, takes an out of patent drug that costs a few bucks, changes the distribution method to make analysis by potential competitors more difficult, and then raise the price by 5555%<\/a>: (No, this is not a decimal place error)<\/p>\n

Specialists in infectious disease are protesting a gigantic overnight increase in the price of a 62-year-old drug that is the standard of care for treating a life-threatening parasitic infection.<\/span>

<\/span> The drug, called Daraprim, was acquired in August by Turing Pharmaceuticals, a start-up run by a former hedge fund manager. Turing immediately raised the price to $750 a tablet from $13.50, bringing the annual cost of treatment for some patients to hundreds of thousands of dollars.<\/span>

<\/span> \u201cWhat is it that they are doing differently that has led to this dramatic increase?\u201d said Dr. Judith Aberg, the chief of the division of infectious diseases at the Icahn School of Medicine at Mount Sinai. She said the price increase could force hospitals to use \u201calternative therapies that may not have the same efficacy.\u201d<\/span>

<\/span> \u2026\u2026\u2026<\/span>

<\/span> The Infectious Diseases Society of America and the HIV Medicine Association sent a joint letter to Turing earlier this month calling the price increase for Daraprim \u201cunjustifiable for the medically vulnerable patient population\u201d and \u201cunsustainable for the health care system.\u201d An organization representing the directors of state AIDS programs has also been looking into the price increase, according to doctors and patient advocates.<\/span>

<\/span> Daraprim, known generically as pyrimethamine, is used mainly to treat toxoplasmosis, a parasite infection that can cause serious or even life-threatening problems for babies born to women who become infected during pregnancy, and also for people with compromised immune systems, like AIDS patients and certain cancer patients.<\/span>

<\/span> \u2026\u2026\u2026<\/span>

<\/span> This is not the first time the 32-year-old Mr. Shkreli, who has a reputation for both brilliance and brashness, has been the center of controversy. He started MSMB Capital, a hedge fund company, in his 20s and drew attention for urging the Food and Drug Administration not to approve certain drugs made by companies whose stock he was shorting.<\/span>

<\/span> In 2011, Mr. Shkreli started Retrophin, which also acquired old neglected drugs and sharply raised their prices. Retrophin\u2019s board fired Mr. Shkreli a year ago. Last month, it filed a complaint in Federal District Court in Manhattan, accusing him of using Retrophin as a personal piggy bank to pay back angry investors in his hedge fund.<\/span>

<\/span> \u2026\u2026\u2026<\/span>

<\/span> With the price now high, other companies could conceivably make generic copies, since patents have long expired. One factor that could discourage that option is that Daraprim\u2019s distribution is now tightly controlled, making it harder for generic companies to get the samples they need for the required testing.<\/span>

<\/span> The switch from drugstores to controlled distribution was made in June by Impax, not by Turing. Still, controlled distribution was a strategy Mr. Shkreli talked about at his previous company as a way to thwart generics.<\/span>

<\/span> \u2026\u2026\u2026<\/span>

<\/span> Dr. Aberg of Mount Sinai said some hospitals will now find Daraprim too expensive to keep in stock, possibly resulting in treatment delays. She said that Mount Sinai was continuing to use the drug, but each use now required a special review.<\/span>

<\/span> \u201cThis seems to be all profit-driven for somebody,\u201d Dr. Aberg said, \u201cand I just think it\u2019s a very dangerous process.\u201d<\/span><\/p><\/blockquote>\n

You can read the details of his looting the last firm he ran here<\/a>.<\/p>\n

I would note that Mr Shkreli is not alone in this behavior: When Glaxo Smith Kline sold the marketing rights to the drug to CorePharma, the price of the drug was $1 a pill, <\/p>\n

Is there anything<\/b> that big finance can’t make destructive and evil?<\/p>\n","protected":false},"excerpt":{"rendered":"

You know the story, hedge fund puke buys a pharmaceutical firm, takes an out of patent drug that costs a few bucks, changes the distribution method to make analysis by potential competitors more difficult, and then raise the price by 5555%: (No, this is not a decimal place error) Specialists in infectious disease are protesting …<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1005,970,1013,969,1004,1074,1150],"tags":[],"class_list":["post-182433","post","type-post","status-publish","format-standard","hentry","category-business","category-corruption","category-drugs","category-evil","category-finance","category-medical","category-public-health"],"_links":{"self":[{"href":"https:\/\/www.panix.com\/~msaroff\/40years\/wp-json\/wp\/v2\/posts\/182433"}],"collection":[{"href":"https:\/\/www.panix.com\/~msaroff\/40years\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.panix.com\/~msaroff\/40years\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.panix.com\/~msaroff\/40years\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.panix.com\/~msaroff\/40years\/wp-json\/wp\/v2\/comments?post=182433"}],"version-history":[{"count":0,"href":"https:\/\/www.panix.com\/~msaroff\/40years\/wp-json\/wp\/v2\/posts\/182433\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.panix.com\/~msaroff\/40years\/wp-json\/wp\/v2\/media?parent=182433"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.panix.com\/~msaroff\/40years\/wp-json\/wp\/v2\/categories?post=182433"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.panix.com\/~msaroff\/40years\/wp-json\/wp\/v2\/tags?post=182433"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}